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Pro198Leu polymorphism aﬀects the selenium
status and GPx activity in response to Brazil nut
intake
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Selenoproteins play important roles in antioxidant mechanisms, and are thus hypothesised to have some
involvement in the pathology of certain types of dementia. Mild cognitive impairment (MCI) and
Alzheimer’s disease (AD) are both thought to involve impaired biological activity of certain selenoproteins.
Previously, supplementation with a selenium-rich Brazil nut (Bertholletia excelsa) has shown potential in
reducing cognitive decline in MCI patients, and could prove to be a safe and eﬀective nutritional approach
early in the disease process to slow decline. Here, we have conducted a pilot study that examined the
eﬀects of a range of single nucleotide polymorphisms (SNPs) in genes encoding the selenoproteins gluta-
thione peroxidase (GPX1) and selenoprotein P (SEPP) in response to selenium supplementation via dietary
Brazil nuts, including selenium status, oxidative stress parameters and GPX1 and SEPP gene expression.
Our data suggest that GPX1 Pro198Leu rs1050450 genotypes may diﬀerentially aﬀect the selenium status
and GPx activity. Moreover, rs7579 and rs3877899 SNPs in SEPP gene, as well as GPX1 rs1050450 geno-
types can inﬂuence the expression of GPX1 and SEPP mRNA in response to Brazil nuts intake. This small
study gives cause for larger investigations into the role of these SNPs in both the selenium status and
response to selenium dietary intake, especially in chronic degenerative conditions like MCI and AD.
Introduction
Despite significant research, strategies to slow the progression
of cognitive decline and the onset of dementia are lacking. It
is estimated that the number of people living with dementia,
such as Alzheimer’s disease which accounts as the main type,
will reach 65.7 million in 2030 and nearly double in 2050.1
Addressing dementia prior to the onset of clinical symptoms is
as important as the development of therapeutics for post-
diagnostic use. Several risk factors linked to lifestyle have been
identified, which include dietary-related conditions such as
midlife obesity, diabetes and hypertension, and if they were to
be reduced by 10–25%, 1.1–3.0 million new AD cases world-
wide could be prevented.2 Accordingly, more attention is being
paid to the role that nutrition plays in the progression of AD
and dementia in general.3,4 However, as is the case in develop-
ing new therapies, diagnosing dementia in its early stages
remains a significant obstacle in identifying beneficial nutri-
tional habits that may reduce the aforementioned risks.
Although some people do not exhibit the explicit clinical
symptoms of dementia, they may develop cognitive impair-
ment beyond what would be expected for normal ageing. This
condition, mild cognitive impairment (MCI), is associated
with an increased risk of dementia and particularly AD, as
brains of MCI patients exhibit many pathological features mir-
roring those of AD subjects.5 There is a high degree of herit-
ability for AD with estimates ranging from 58 to 79%,6 with a
number of genetic risk factors shared with MCI.7 Single
nucleotide polymorphisms (SNPs) in amyloid precursor
protein (APP) and presenilin-1 (PSEN1) and 2 (PSEN2) genes
have been implicated in the predisposition of early-onset
familial AD;8–11 and SNPs in the genes encoding apolipo-
protein E (APOE) and α2-macroglobulin (A2M) are associated
with late-onset AD.12,13 Genome wide association studies
(GWAS) have identified several additional genes that appear to
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predict AD susceptibility,14 and the biological pathways in
which they participate support several hypotheses regarding
upstream AD pathology, including chronic inflammation, lipid
transport and β-amyloid processing. Considering that oxidative
stress has a central role in neurodegeneration, cognitive
decline and AD in particular, it is important to understand the
role of SNPs involved with antioxidant enzymes.
Selenium (Se) is an essential element in the central nervous
system and deficiency has been associated with cognitive
decline.15–17 Selenium deficiency may be compounded
by SNPs in genes encoding selenoproteins and negatively influ-
ence the normally protective roles against oxidative stress
played by many of the 25 identified Se-containing
proteins.18–20 Jablonska et al.21 and Cominetti et al.22
suggested that the SNP Pro198Leu (reference SNP identifi-
cation number rs1050450) in the glutathione peroxidase 1
(GPX1) gene might aﬀect the antioxidant activity. Additionally,
a diﬀerential correlation between erythrocyte GPx activity and
erythrocyte Se levels according to Pro198Leu genotype has
been observed,23 and Paz-Y-Miño et al.24 reported an associ-
ation between the variant allele and increased risk for AD. The
gene encoding selenoprotein P (SEPP) has several known SNPs,
of which rs7579 (G/A substitution in the 3′-untranslated
region) and rs3877899 were reported to have functional conse-
quences on both the protein level and function.25–28
Brazil nuts (Bertholletia excelsa) are the richest food source
of Se, and inclusion of this nut in the diet may be a viable
strategy to increase dietary intake of Se. The high Se content in
Brazil nuts is mainly as selenomethionine, the most bioavail-
able form of dietary Se.29 Suﬃcient Se intake and associated
Se levels may be related to a decreased risk for AD.30–32
However, the aforementioned SNPs in genes encoding seleno-
proteins may influence the response to a dietary inter-
vention,33 and thus, it is critical to understand the interaction
between Se intake and genetic variation in selenoprotein
homeostasis. The aims of this study were to evaluate the impli-
cations of GPX1 rs1050450 and SEPP rs7579 and rs3877899
SNPs on Se status and oxidative stress biomarkers in MCI
patients, and to determine if these SNPs aﬀect the response to
supplemental Se intake from Brazil nuts.
Experimental
Study design
All procedures followed in this study have been performed in
accordance with the ethical standards as laid down in the 1964
Declaration of Helsinki and its later amendments. They were
reviewed and approved by the Ethics Committee of Faculty of
Pharmaceutical Sciences at the University of São Paulo – Brazil
(protocol number: 568). Informed consent was obtained from
all individual participants and included in the study. The trial
was registered at ClinicalTrials.gov under identification
number NCT02121457.
The study was conducted on patients diagnosed with MCI
according to the criteria proposed by the International
Working Group on Mild Cognitive Impairment.34 They
attended the Memory and Aging Unit of the Geriatrics Division
at the University of São Paulo Medical School (Brazil) during
the period May 2011 to August 2012. Among the patients, 31
fulfilled the following inclusion criteria: age 60+ years; fluent
in Portuguese language; absence of any other significant
neurologic or psychiatric diseases; no regular intake of Brazil
nuts or Se-containing supplements; and no intolerance to olea-
ginous food.
To investigate if the SNPs influenced the response to daily
Brazil nut intake, we examined a randomised subgroup with
11 participants who consumed one Brazil nut daily for
6 months, as described elsewhere.32 The nuts were oﬀered
every 2 months in a bag containing 60 nuts. Compliance was
monitored by counting the number of nuts returned at the
conclusion of the study. A subject was considered compliant if
≥85% of the Brazil nuts were consumed. All subjects were
instructed to maintain their normal diet and to avoid
additional Brazil nuts during the study. The nutritional infor-
mation of Brazil nuts used is given in Table 1, considering that
the mean weight of one nut was 5 g, and each nut provided
about 288.8 µg of Se.32
Biochemical assays
Erythrocyte GPx activity was measured according to the
method described by Paglia and Valentine35 with the Ransel
505 kit (RANDOX Laboratories, Crumlin, UK) using a bio-
chemical analyser (Liasys® MAS, Rome, Italy). Malondialde-
hyde (MDA) was measured in plasma by high performance
liquid chromatography (HPLC) on a Shimadzu (Kyoto, Japan)
instrument with a Phenomenex (Torrance, CA, USA) reverse-
phase C18 column according to the method described by
Hong et al.36 The instrument was calibrated with a MDA stan-
dard stock solution in the following concentrations: 0.0, 0.25,
0.5, 1.0, 2.0, 4.0, 6.0 and 12.0 µM. Oxygen radical absorbance
capacity (ORAC) was measured following the method described
by Prior et al.37 using a Synergy H1 multi-mode microplate
reader (Biotek Instruments, Winooski, VT, USA). The instru-
ment was calibrated with Trolox prepared with phosphate
buﬀer in the following concentrations: 100 µM, 50 µM, 25 µM,
12.5 µM, 6.25 µM. Samples were analysed in triplicate.
Selenium levels in plasma and erythrocytes were analysed
using hydride generation atomic absorption spectroscopy
(AAS).38 Samples were prepared in duplicate and measure-
ments were made in triplicate, equaling six readings per
person. Method validity was maintained by a measured Se
Table 1 Average nutritional values of Brazil nuts (Bertholletia excelsa)
used in this study.31 Concentration values are per gram of total nut mass
Carbohydrate (mg g−1) 108.9
Protein (mg g−1) 162.7
Lipids (mg g−1) 673.5
Se (μg g−1) 57.75
Mean Se per nut (μg) 288.8
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recovery of at least 85% of the certified content of a lyophilised
human reference control (Seronorm Trace Elements Serum
and Whole Blood; Sero AS, Billingstad, Norway).
Genotyping of the rs1050450, rs7579 and rs3877899 SNPs
Isolation of DNA from whole blood was carried out using a
PureLink Genomic DNA kit (Invitrogen, Life Technologies Inc.,
Carlsbad, CA, USA), and the concentration was measured
using a NanoDrop ND 1000 spectrophotometer (Thermo Scien-
tific, Wilmington, DE, USA).
Polymorphisms of GPX1 (rs1050450) and SEPP (rs7579 and
rs3877899) genes were determined by real-time polymerase
chain reaction (RT-PCR) with TaqMan SNP Genotyping assays
(Life Technologies, Foster City, CA, USA). The assays were
obtained as pre-designed from Applied Biosystems for rs7579
and rs3877899 (ID Assays C___8806056_10 and
C___2841533_10, respectively) and custom-made through
Custom TaqMan® Genomic Assays service for rs1050450. The
RT-PCR reaction contained 12.5 µL of 1× TaqMan Genotyping
Master Mix (Life Technologies), 1.25 µL of the 20× SNP
Genotyping Assay (Life Technologies) and 20 ng of genomic
DNA in a 20 μL total reaction volume.
Samples were assayed along with no-template and HapMap
controls and run on a StepOne Real-Time PCR System under
the following conditions: an initial enzyme activation step at
94 °C for 10 min followed by 40 cycles at 92 °C for 15 s and
60 °C for 1 min for annealing and extension.
GPX1 and SEPP gene expression
GPX1 and SEPP gene expression were assessed in the subgroup
composed of 11 participants who consumed Brazil nuts in
order to evaluate their eﬀect. mRNA was extracted from whole
blood by using the RiboPure™ – Blood Kit (Life Technologies)
and treated with DNase I to avoid DNA contamination. RNA
was stored under −80 °C for further analysis. The final concen-
tration was measured using a NanoDrop ND 1000 spectrophoto-
meter (Thermo Scientific), and RNA integrity was considered
acceptable when the absorbance ratios in 260 and 280 nm
wavelengths were between 1.8 and 2. SuperScript® III Reverse
Transcriptase (Invitrogen, Carlsbad, CA, USA, Cat #18080093)
was used for reverse transcription, and the cDNA was adjusted
to a concentration of 20 ng µL−1 in a final volume of 20 µL.
Analysis of GPX1 and SEPP mRNA expression was carried
out for each sample by real-time quantitative PCR (qPCR)
assay on a StepOne Real-Time PCR System using specific
hydrolysis probes (TaqMan® Gene Expression Assays – ID
Assays Hs00829989_gH and Hs01032845_m1, respectively for
GPX1 and SEPP) (Life Technologies). The qPCR were performed
in duplicate and the samples contained 4 µL of cDNA, 10 µL of
TaqMan® Universal Master Mix II (Life Technologies), 1 µL of
the 20× TaqMan® Gene Expression Assay and 5 µL of RNase-
free water in a 20 µL final volume. β-Actin was used as a refer-
ence gene as its expression was very stable among participants.
A non-template (without cDNA) reaction was included with
each qPCR run to serve as a negative control. The cycling
qPCR for each sample started with a denaturation step at
50 °C for 2 min, followed by 45 cycles at 95 °C for 15 s, and
1 min at 60 °C for hybridisation and extension.
To evaluate the diﬀerential expression of GPX1 and SEPP
among diﬀerent genotypes for rs1050450, rs7579 and
rs3877899, the ΔCq was normalised to the internal control
gene β-actin, and so the results are expressed by [Cq target
gene − Cq reference gene].
Assessment of selenium intake
Selenium intake was evaluated using a 3-day (2 weekdays and
1 weekend day) non-consecutive dietary food record. The sele-
nium content in the diet was based on the levels determined
by Ferreira et al.39 from the analysis of Se concentrations in
Brazilian foods. These records were analysed using the
NutWin Software (Escola Paulista de Medicina/UNIFESP/
Brazil).
Statistical analysis
Individuals who scored homozygous and heterozygous for
allele variants were pooled and compared against wild types
for all statistical analyses. Descriptive statistical analysis was
performed, and all continuous variables are expressed as
mean ± standard deviation (SD). Categorical variables were
expressed using both a number and percentage. Variable dis-
tribution was evaluated using the Shapiro–Wilk W test. Allele
frequencies were estimated using the gene-counting method.
Diﬀerences between genotypes were assessed using Stu-
dent’s t-test for independent samples. Hierarchical multiple
linear regression analysis was used to examine the association
between Se status and genotypes for rs1050450, rs7579 and
rs3877899 while controlling the other potentially confounding
variables. Consequently, we designed models in which the
genotype was used as the primary independent variable and
plasma and erythrocyte Se levels were alternately used as the
dependent variable. Covariates were entered in three sequen-
tial steps to examine their incremental validity: in the first
step, the genotype was entered without covariates; in the
second step, age and sex were entered; in the third step, Se
intake was assessed. To evaluate the association between the
genotype and oxidative stress parameters for the SNPs, ORAC,
MDA and GPx activity were used alternately as dependent vari-
ables in discrete regression models. In these models, geno-
types were also used as the primary independent variables,
and covariates were entered as follows: (i) genotype without
covariates; (ii) erythrocyte Se; and (iii) socio-demographic vari-
ables (sex and age) entered as a block. Pearson’s correlation
coeﬃcient was used to estimate the correlation between GPx
activity and the Se level in erythrocytes.
To describe the relationship between aspects of food con-
sumption and biochemical characteristics independent of
energy intake, Se intake was adjusted by energy intake accord-
ing to Willet40 using linear regression (linear regression of
nutrient intake on total caloric intake) and the addition of a
constant (mean energy intake of the group).
The post-supplementation data were compared with the
baseline data using a paired Student’s t-test or Wilcoxon test
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as appropriate. The diﬀerences in the outcome measures
between genotype groups over time were analysed using an
independent sample Student’s t-test when the data presented
normal distribution or were continuous. Alternatively, a
Mann–Whitney U-test for non-parametric variables was
conducted.
All statistical analyses were performed using the Statistical
Package for the Social Sciences software Version 20.0 for
Windows (SPSS, Chicago, IL, USA), and a p value <0.05 was
considered to be statistically significant. Figures displaying
statistical analysis were produced using Prism 6 (GraphPad, La
Jolla, CA, USA).
Results
Twenty participants fulfilled the aforementioned criteria and
were included in this study. The mean age was 77.7 ± 5.3
(range = 70.0–92.0) years, and 30% were male. These character-
istics of study population were not diﬀerent among genotype
groups. Genotype distribution and variant allele frequencies
for the GPX1 rs1050450, SEPP rs7579 and SEPP rs3877899 poly-
morphisms are shown in Table 2. The selenium status and
intake, GPx activity, ORAC and MDA levels on the baseline for
all genotypes are shown in Table 3. No significant diﬀerences
were observed regarding biochemical parameters among
diﬀerent genotypes.
Linear regression models suggest that the presence of one
or two variant alleles (CT or TT genotypes) for GPX1 rs1050450
was associated with higher Se plasma levels (+0.613 μg L−1 SD
per allele; p < 0.05). The rs7579 and rs3877899 polymorphisms
were not associated with the Se status, and none of the evalu-
ated genotypes showed associations with changes in either
MDA or ORAC oxidative stress markers. In contrast, age was
associated with lower GPx activity when adjusted by genotype,
sex and erythrocyte Se levels (β coeﬃcient = −0.403, −0.449,
−0.452, respectively for rs1050450, rs7579 and rs3877899).
Although a t-test revealed higher Se intake in T-allele carriers
(rs1050450), regression models showed no influence of Se
intake on the measured biochemical parameters.
The correlation between GPx activity and erythrocyte Se con-
centration varied among the tested genotypes. For the GPX1
genotypes, this correlation was observed only in CC genotypes
(r = 0.803, p < 0.05), but not in T-allele carriers (r = 0.531, p =
0.08). The same pattern of correlation was verified in subjects
carrying the GG genotype regarding SEPP rs3877899 (r = 0.645,
p < 0.05) in contrast to the GA individuals (r = 0.568, p = 0.14).
When the correlation between GPx activity and erythrocyte Se
content was analysed according to rs7579 genotype groups, we
observed significance only for the GA + AA genotypes (r =
0.939, p < 0.001).
Among the 20 participants of the study, 11 were randomly
assigned to receive one Brazil nut daily for six months. We
reported previously that the intake of this nut increased GPx
activity with a corresponding elevation in plasma and erythro-
cyte Se levels, while not influencing the levels of ORAC and
MDA.32 In this experimental group, we found that: (i) accord-
ing to genotypes before and after baseline measurement, we
observed highly significant post-supplementation diﬀerences
compared to pre-treatment for Se-related variables (blood Se
and GPx activity); and (ii) an intragroup (between genotypes)
comparison demonstrates that the genotype does not influ-
ence these variables (Table 4).
However, we observed that GPX1 and SEPP mRNA
expression in response to Brazil nut intake was diﬀerent
among genotypes. In carriers of a variant allele (CT + TT) for
rs1050450, GPX1 and SEPP mRNA expression increased over
time and no significant diﬀerences were observed for CC
carriers. SEPP mRNA expression also increased after treatment
in A-carriers for rs7579 and GG genotype for rs3877899. On the
other hand, GPX1 mRNA expression reduced significantly in
A-carriers for rs7579 and GG carriers of rs3877899 (Fig. 1).
Discussion
This pilot study is the first to analyse the association between
the Se status and oxidative stress markers in MCI patients with
respect to selenoprotein SNPs. We hypothesised that the GPX1
rs1050450 and SEPP rs7579 and rs3877899 polymorphisms
would influence Se parameters and oxidative stress biomarkers
in these patients, as well as the response to Se intake via Brazil
nuts.
The rs1050450 polymorphism has been associated with an
increased risk for AD,24 although the precise mechanism by
which this SNP influences AD and MCI pathogenesis is
unclear. Here, we observed that none of the GPX1 genotype
groups had diﬀerent plasma and erythrocyte Se levels;














rs1050450 (C > T) 8 (40%) 7 (35%) 5 (25%) 12 (60%) 0.425
SEPP
rs7579 (G > A) 11 (55%) 6 (30%) 3 (15%) 9 (45%) 0.300
rs3877899 (G > A) 12 (60%) 8 (40%) 0 (0%) 8 (40%) 0.200
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however, in fully adjusted logistic regression models the pres-
ence of T allele of GPX1 was associated with higher plasma Se.
These results suggest that this SNP might aﬀect the way in
which the body metabolises and utilises Se, although they con-
trast with previous studies that did not observe diﬀerences in
the Se status as a result of the Pro198Leu polymorphism.22,23
As observed in other studies,41–44 oxidative stress parameters
were not aﬀected by Pro198Leu genotypes. However, studies
have associated the presence of the T allele with decreased GPx
activity,27,45–47 and we observed that T carriers had 20% lower
GPx activity in comparison with the CC genotype, although
this diﬀerence was not statistically significant. Moreover, the
correlation between GPx activity and erythrocyte Se concen-
tration was significant only in TT genotypes, which allow us to
hypothesise that post-transcription regulation might be occur-
ring due to Pro198Leu genotypes. Studies have shown that GPx
activity may plateau over certain Se levels.47 However, we
observed a positive correlation between erythrocyte GPx activity
and erythrocyte Se level only in CC genotype, suggesting that
the GPx activity plateau varies according to the genotype. Con-
sidering the known association between decreased GPx activity
in AD,18 these data suggest that, at least in MCI patients, the
ability of the body to uptake Se and incorporate it into seleno-
proteins is influenced by the Pro198Leu genotype, which may
explain the findings of Paz-y-Miño et al.,24 who reported an
association between T allele and the risk of AD. This further
supports a potential role for GPx in cognitive decline and the
benefits of Se supplementation. Further investigation is
required to confirm the eﬀects of Pro198Leu on Se metabolism
and requirements.
The SEPP polymorphism rs7579 is located in a region
corresponding to the 3′-UTR,26 where a UGA codon is read as a
selenocysteine (Sec) codon during selenoprotein synthesis.48
This SNP may alter the eﬃciency of Sec incorporation into
SePP.49 The rs3877899 polymorphism is located in the coding
region of the SEPP gene and may regulate the stability of SePP
protein and cellular Se uptake.26 In our study, the rs7579 and
rs3877899 SNPs neither influenced the Se status, nor oxidative
stress parameters, although both have been associated with a
change in the proportion of 50- and 60-kDa SePP isoforms in
plasma, which may aﬀect Se supply for the synthesis of
diﬀerent selenoproteins, including antioxidant enzymes, in
diﬀerent tissues.26
As oxidative stress has a central role in neurodegeneration
and cognitive decline, inclusion of foods with antioxidant
characteristics may be a worthwhile strategy to improve antiox-
idant capacity and reduce the risk of dementia with no other-
wise ill-eﬀects. Brazil nuts are unique due to their high Se
content50,51 and potentially beneficial phenolic compounds.52
Following our previous evidence that regular Brazil nuts intake
increased Se levels in MCI patients,32 we observed here that
GPX1 or SEPP genotypes did not influence biomarkers of Se
status. However, we did observe that the change in GPX1 and
SEPP expression over time was not equivalent across genotype
groups. Carriers of T-allele of Pro198Leu were more responsive
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SEPP mRNA expression. Moreover, although not significant,
we observed that CT + TT genotypes for Pro198Leu had higher
GPx activity over time in comparison with the CC genotype.
Taking together, these observations build up the hypothesis
that Pro198Leu genotypes should be considered in studies that
assess both the selenium nutritional status and the eﬀect of
selenium intake. The rs7579 and rs3877899 SNPs in SEPP gene
also resulted in diﬀerent changes on mRNA expression over
time: a-allele of rs7579 was associated with decreased GPX1
and increased SEPP mRNA expression over time, and the same
variation was observed for the GG genotype of rs3877899. Pre-
vious studies have shown that Se supplementation increased
GPX153–57 and SEPP49,53,56,57 expression. However, we highlight
that these studies assessed gene expression in enterocytes and
hepatocytes in cell cultures and in vivo animal studies, and did
not consider genotypes. Thus, we emphasise the need for
more studies to understand the as-yet unknown mechanisms
that possibly interact during selenoprotein synthesis, as
changes in SePP synthesis can aﬀect not only the function of
the protein itself but also other selenoproteins that are
involved in selenium hierarchy.33
Diﬀerent environmental characteristics can be related to
Se status and metabolism.58 In our study, age was negatively
correlated with GPx activity, but not with the Se status,
corroborating the results of Maurya et al.59 and contrasting
those of Ferguson et al.47 The real association between age
and selenoprotein metabolism should be further investigated,
because it is hypothesised that GPx variation with age could
be due to variability of Se availability.60 Body mass index
can also aﬀect Se metabolism, as obese people with the GG
genotype are more responsive to Se supplementation.26 In
our study, no diﬀerences in body mass index (BMI) were
observed between groups (p = 0.107), and only one participant
presented a BMI > 30, which precluded such analysis. It
was not possible to see the eﬀect of sex on biochemical
parameters due to the small size of this pilot study. It is
also important to note that multiple variants in
selenoprotein genes and in the genes of other antioxidant
enzymes may act synergistically to generate a diﬀerent
downstream response; as a result, the eﬀects of a given SNP
may be altered by SNPs in other genes.33 Therefore,
larger studies building on our pilot data that examine SNPs
Table 4 Selenium status, GPx activity and MDA levels of the GPX1 and SEPP genes at the baseline and after 6 months of treatment based on the
participants’ genotypes for the GPX1 rs1050450 and the SEPP rs7579 and rs3877899 gene polymorphisms (n = 11). Pre = pre-treatment; post =
post-treatment
Pre ± SD Post ± SD Change (95% CI)
p-Value for between
genotype comparisona
Selenium plasma (µg L−1)
GPX1 rs1050450 CC 49.90 ± 10.31 246.19 ± 53.99 196.29* (110.40–282.18) 0.140
CT + TT 59.86 ± 21.56 315.92 ± 75.80 256.06* (197.37–314.75)
SEPP rs7579 GG 59.62 ± 21.32 277.79 ± 62.09 218.16* (174.44–261.87) 0.405
GA + AA 50.32 ± 11.73 312.93 ± 98.88 262.60* (121.58–406.62)
SEPP rs3877899 GG 52.77 ± 11.97 299.91 ± 68.68 247.13* (186.35–307.92) 0.423
GA 62.31 ± 27.51 274.21 ± 92.40 211.91*(107.48–316.33)
Selenium erythrocyte (µg L−1)
GPX1 rs1050450 CC 65.11 ± 13.62 519.23 ± 239.80 454.12* (84.03–824.22) 0.290
CT + TT 56.37 ± 24.20 606.18 ± 151.23 549.81* (429.04–670.57)
SEPP rs7579 GG 58.17 ± 22.53 536.64 ± 116.86 478.47* (379.64–577.30) 0.372
GA + AA 61.96 ± 19.83 640.93 ± 270.41 578.97* (174.67–983.27)
SEPP rs3877899 GG 57.14 ± 16.96 607.44 ± 177.57 550.29* (397.63–702.96) 0.416
GA 63.75 ± 28.43 517.02 ± 199.14 453.27* (162.11–744.43)
GPx activity (U g−1 Hb)
GPX1 rs1050450 CC 54.00 ± 10.29 67.67 ± 8.93 13.66* (4.67–22.65) 0.555
CT + TT 33.15 ± 12.15 54.91 ± 24.73 21.76* (−9.38–52.91)
SEPP rs7579 GG 36.39 ± 15.08 64.92 ± 20.30 28.53* (6.03–51.03) 0.122
GA + AA 48.33 ± 13.94 50.15 ± 20.79 1.81 (−36.08–39.72)
SEPP rs3877899 GG 39.64 ± 16.26 62.33 ± 24.76 22.68 (−8.15–53.52) 0.440
GA 42.64 ± 15.28 54.68 ± 12.88 12.04* (2.45–21.64)
MDA (μmol L−1)
GPX1 rs1050450 CC 0.38 ± 0.04 0.47 ± 0.14 0.09 (−0.09–0.28) 0.926
CT + TT 0.44 ± 0.05 0.54 ± 0.12 0.10 (−0.06–0.26)
SEPP rs7579 GG 0.42 ± 0.03 0.51 ± 0.13 0.09 (−0.39–0.21) 0.746
GA + AA 0.41 ± 0.08 0.53 ± 0.13 0.12 (−0.15–0.39)
SEPP rs3877899 GG 0.41 ± 0.06 0.50 ± 0.14 0.09 (−0.05–0.22) 0.597
GA 0.42 ± 0.02 0.55 ± 0.07 0.13 (−0.09–0.35)
aUnpaired Student’s t-test. *Significantly diﬀerent from baseline; p < 0.05 (Student’s t-test).
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in selenoprotein genes and other genes in relationship
to diﬀerent environmental and dietary factors will be
invaluable.
Conclusions
Our findings suggest that the GPX1 rs1050450 polymorphism
may influence Se status and selenoprotein synthesis, although
it did not aﬀect the direct response to Brazil nut intake with
respect to Se levels, as well as observed in rs7579 and
rs3877899 genotypes. However, we found that both GPX1 and
SEPP expression in response to Brazil nut intake was aﬀected
by rs1050450, rs7579 and rs3877899 genotypes. This pilot data
justifies a need for further studies to better understand the
eﬀects of these SNPs in response to dietary Se and determine
the mechanism by which Se slows cognitive decline, and thus
we aim to enlarge the sample size and generate more data
moving forward.
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